Skip to main content
Top

Open Access 09-07-2024 | Breast Cancer | REVIEW AND PERSPECTIVES

Neuroendocrine neoplasms of the breast: a review of literature

Authors: Federica Vegni, Ilenia Sara De Stefano, Federica Policardo, Pietro Tralongo, Angela Feraco, Angela Carlino, Giulia Ferraro, Qianqian Zhang, Giulia Scaglione, Nicoletta D’Alessandris, Elena Navarra, Gianfranco Zannoni, Angela Santoro, Antonino Mule, Esther Diana Rossi

Published in: Virchows Archiv

Login to get access

Abstract

Primary neuroendocrine neoplasms (NENs) of the breast are characterized by neuroendocrine architectural and cytological features, which must be supported by immunohistochemical positivity for neuroendocrine markers (such as Chromogranin and Synaptophysin). According to the literature, making a diagnosis of primary neuroendocrine breast cancer always needs to rule out a possible primary neuroendocrine neoplasm from another site. Currently, the latest 2022 version of the WHO of endocrine and neuroendocrine neoplasms has classified breast NENs as well-differentiated neuroendocrine tumours (NETs) and aggressive neuroendocrine carcinomas (NECs), differentiating them from invasive breast cancers of no special type (IBCs-NST). with neuroendocrine features. The current review article describes six cases from our series and a comprehensive review of the literature in the field of NENs of the breast.
Literature
1.
go back to reference Board WCoTE (2019) Breast tumours , WHO classification of tumors, 5nd edn. World Health Organization, Geneva, pp 1–28 Board WCoTE (2019) Breast tumours , WHO classification of tumors, 5nd edn. World Health Organization, Geneva, pp 1–28
4.
go back to reference Tsang JY, Tse GM (2021) Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Modern PathoL 34:1062–1073CrossRef Tsang JY, Tse GM (2021) Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Modern PathoL 34:1062–1073CrossRef
6.
go back to reference Ellis IO, Schnitt SJ, Sastre-Garau X et al (2003) Tumors of the breast, neuroendocrine tumours. In: Tavassooli FA, Devilee P et al (eds) World Health Organization Classification of tumours, pathology and genetics of tumours of the breast and female genital organs. IARC, Lyon, p 3264 Ellis IO, Schnitt SJ, Sastre-Garau X et al (2003) Tumors of the breast, neuroendocrine tumours. In: Tavassooli FA, Devilee P et al (eds) World Health Organization Classification of tumours, pathology and genetics of tumours of the breast and female genital organs. IARC, Lyon, p 3264
8.
go back to reference Christie M, Chin-Lenn L, Watts MM, Tsui AE, Buchanan MR (2010) Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situ. Int J Clin Exp Pathol 3(6):629–633PubMedPubMedCentral Christie M, Chin-Lenn L, Watts MM, Tsui AE, Buchanan MR (2010) Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situ. Int J Clin Exp Pathol 3(6):629–633PubMedPubMedCentral
13.
go back to reference Wei B, Ding T, Xing Y et al (2010) Invasive neuroendocrine carcinoma of the breast: a distinct subtype of aggressive mammary carcinoma. Cancer 116(19):4463–4473CrossRefPubMed Wei B, Ding T, Xing Y et al (2010) Invasive neuroendocrine carcinoma of the breast: a distinct subtype of aggressive mammary carcinoma. Cancer 116(19):4463–4473CrossRefPubMed
14.
go back to reference Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL (2014) Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat 148(1):637–664CrossRefPubMed Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL (2014) Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat 148(1):637–664CrossRefPubMed
15.
go back to reference Zhang Y, Chen Z, Bao Y et al (2013) Invasive euroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma 60(2):215–222CrossRefPubMed Zhang Y, Chen Z, Bao Y et al (2013) Invasive euroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma 60(2):215–222CrossRefPubMed
16.
go back to reference Park WM, Wu Y, Wei W, Yang WT (2014) Primary neuroendocrine carcinoma of the breast: clinical, imaging and histologic features. AJR Am J Roentgenol 203(2):W221–W230CrossRefPubMed Park WM, Wu Y, Wei W, Yang WT (2014) Primary neuroendocrine carcinoma of the breast: clinical, imaging and histologic features. AJR Am J Roentgenol 203(2):W221–W230CrossRefPubMed
23.
go back to reference Krawczyk N, Röwer R, Anlauf M, Muntanjohl C, Baldus SE, Neumann M, Banys-Paluchowski M, Otten S, Luczak K, Ruckhäberle E, Mohrmann S, Hoffmann J, Kaleta T, Jaeger B, Esposito I, Fehm T (2022) Invasive breast carcinoma with neuroendocrine differentiation: a single-center analysis of clinical features and prognosis. Geburtshilfe Frauenheilkd 82:68–84CrossRefPubMed Krawczyk N, Röwer R, Anlauf M, Muntanjohl C, Baldus SE, Neumann M, Banys-Paluchowski M, Otten S, Luczak K, Ruckhäberle E, Mohrmann S, Hoffmann J, Kaleta T, Jaeger B, Esposito I, Fehm T (2022) Invasive breast carcinoma with neuroendocrine differentiation: a single-center analysis of clinical features and prognosis. Geburtshilfe Frauenheilkd 82:68–84CrossRefPubMed
24.
go back to reference Papotti M, Macrì L, Finzi G, Capella C, Eusebi V, Bussolati G (1989) Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol 6:174–188PubMed Papotti M, Macrì L, Finzi G, Capella C, Eusebi V, Bussolati G (1989) Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol 6:174–188PubMed
29.
go back to reference Rakha EA, Reis-Filho JS, Sasano H, Wu Y (2019) Neuroendocrine neoplasms: introduction, neuroendocrine tumor, neuroendocrine carcinoma. WHO Classification of Tumours Editorial Board. Breast tumours, 5th edn. International Agency for Research on Cancer, Lyon, France, pp 155–161 Rakha EA, Reis-Filho JS, Sasano H, Wu Y (2019) Neuroendocrine neoplasms: introduction, neuroendocrine tumor, neuroendocrine carcinoma. WHO Classification of Tumours Editorial Board. Breast tumours, 5th edn. International Agency for Research on Cancer, Lyon, France, pp 155–161
30.
go back to reference Papotti M, Macri L, Bussolati G (1989) Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer 43:365–369CrossRefPubMed Papotti M, Macri L, Bussolati G (1989) Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer 43:365–369CrossRefPubMed
32.
go back to reference Kumar U, Grigorakis SI, Watt HL (2005) Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 92:175–186CrossRefPubMed Kumar U, Grigorakis SI, Watt HL (2005) Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 92:175–186CrossRefPubMed
33.
go back to reference Buscail L, Esteve JP, Saint-Laurent N (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A 92:1580–1584CrossRefPubMedPubMedCentral Buscail L, Esteve JP, Saint-Laurent N (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A 92:1580–1584CrossRefPubMedPubMedCentral
34.
go back to reference Terlevic R, Peric Balja M, Tomas D (2019) Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer. Ann Diagn Pathol 38:62–66CrossRefPubMed Terlevic R, Peric Balja M, Tomas D (2019) Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer. Ann Diagn Pathol 38:62–66CrossRefPubMed
35.
go back to reference ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, Pavel M, Öberg K, Falconi M (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:844–860CrossRef ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, Pavel M, Öberg K, Falconi M (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:844–860CrossRef
36.
go back to reference Dolan JT, Miltenburg DM, Granchi TS (2001) Treatment of metastatic breast cancer with somatostatin analogues–a meta-analysis. Ann Surg Oncol 8:227–233PubMed Dolan JT, Miltenburg DM, Granchi TS (2001) Treatment of metastatic breast cancer with somatostatin analogues–a meta-analysis. Ann Surg Oncol 8:227–233PubMed
37.
go back to reference Chapman JA, Costantino JP, Dong B (2015) Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat. 153:353–360CrossRefPubMedPubMedCentral Chapman JA, Costantino JP, Dong B (2015) Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat. 153:353–360CrossRefPubMedPubMedCentral
39.
go back to reference Mohanty SK, Kim SA, DeLair DF et al (2016) Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation. Mod Pathol 29(8):788–798CrossRefPubMed Mohanty SK, Kim SA, DeLair DF et al (2016) Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation. Mod Pathol 29(8):788–798CrossRefPubMed
40.
go back to reference Perry KD, Reynolds C, Rosen DG et al (2011) Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology 59(4):619–630CrossRefPubMed Perry KD, Reynolds C, Rosen DG et al (2011) Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology 59(4):619–630CrossRefPubMed
41.
go back to reference Guo A, Wang Y, Rohr J et al (2016) Solid papillary carcinoma of the breast: a special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. Breast 26(1):67–72CrossRefPubMed Guo A, Wang Y, Rohr J et al (2016) Solid papillary carcinoma of the breast: a special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. Breast 26(1):67–72CrossRefPubMed
43.
go back to reference Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G et al (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39. https://doi.org/10.1016/S1470-2045(17)30777-5CrossRef Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G et al (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39. https://​doi.​org/​10.​1016/​S1470-2045(17)30777-5CrossRef
46.
go back to reference Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M, Panelists of the St Gallen Consensus Conference (2021) Customizing local and systemic therapies for women with early breast cancer: the St Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32(10):1216–1235. https://doi.org/10.1016/j.annonc.2021.06.023CrossRefPubMed Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M, Panelists of the St Gallen Consensus Conference (2021) Customizing local and systemic therapies for women with early breast cancer: the St Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32(10):1216–1235. https://​doi.​org/​10.​1016/​j.​annonc.​2021.​06.​023CrossRefPubMed
47.
go back to reference Jagsi R, Hawley ST, Griffith KA et al (2017) Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg 152:274–282CrossRefPubMedPubMedCentral Jagsi R, Hawley ST, Griffith KA et al (2017) Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg 152:274–282CrossRefPubMedPubMedCentral
49.
go back to reference Boutrid H, Kassem M, Tozbikian G, Morgan E, White J, Shah M, VanDeusen J, Sardesai S, Williams N, Stover D, et al (2020) TTF-1 positive primary small cell carcinoma of the breast: a case report and review of the literature. Front Endocrinol 11. https://doi.org/10.3389/fendo.2020.00228 Boutrid H, Kassem M, Tozbikian G, Morgan E, White J, Shah M, VanDeusen J, Sardesai S, Williams N, Stover D, et al (2020) TTF-1 positive primary small cell carcinoma of the breast: a case report and review of the literature. Front Endocrinol 11. https://​doi.​org/​10.​3389/​fendo.​2020.​00228
58.
go back to reference Gatalica Z, Feldman R, Ghazalpour A, Vranic S. (2017) Abstract nr P6–07–27: characterization of neuroendocrine breast carcinomas for biomarkers of therapeutic options. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium, San Antonio, TX. Philadelphia (PA): AACR, Cancer Res 77(4 Suppl) Gatalica Z, Feldman R, Ghazalpour A, Vranic S. (2017) Abstract nr P6–07–27: characterization of neuroendocrine breast carcinomas for biomarkers of therapeutic options. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium, San Antonio, TX. Philadelphia (PA): AACR, Cancer Res 77(4 Suppl)
59.
go back to reference Lamarca A, Frizziero M, Barriuso J, McNamara MG, Hubner RA, Valle JW (2019) Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC9. Clin Translational Oncol 21(7):950–953. https://doi.org/10.1007/s12094-018-1996-zCrossRef Lamarca A, Frizziero M, Barriuso J, McNamara MG, Hubner RA, Valle JW (2019) Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC9. Clin Translational Oncol 21(7):950–953. https://​doi.​org/​10.​1007/​s12094-018-1996-zCrossRef
60.
go back to reference Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J, Japan Clinical Oncology Group (JCOG) (2022) Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol 8(10):1447–1455. https://doi.org/10.1001/jamaoncol.2022.3395CrossRefPubMedPubMedCentral Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J, Japan Clinical Oncology Group (JCOG) (2022) Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol 8(10):1447–1455. https://​doi.​org/​10.​1001/​jamaoncol.​2022.​3395CrossRefPubMedPubMedCentral
66.
go back to reference Burstein HJ, Lacchetti C, Anderson H, Buchholz T, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V et al (2019) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37:423–438. https://doi.org/10.1200/JCO.18.01160CrossRefPubMed Burstein HJ, Lacchetti C, Anderson H, Buchholz T, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V et al (2019) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37:423–438. https://​doi.​org/​10.​1200/​JCO.​18.​01160CrossRefPubMed
68.
go back to reference Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541–1547. https://doi.org/10.1093/annonc/mdy155CrossRefPubMed Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541–1547. https://​doi.​org/​10.​1093/​annonc/​mdy155CrossRefPubMed
84.
go back to reference Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519–530. https://doi.org/10.1016/S1470-2045(19)30863-0CrossRefPubMed Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519–530. https://​doi.​org/​10.​1016/​S1470-2045(19)30863-0CrossRefPubMed
92.
go back to reference Li Y, Cao Y, Wu X, Liu R, Wang K (2022) HER-2-positive primary neuroendocrine neoplasms of the breast with signet ring feature: a case report and review of literature. Front Oncol 12:34–43 Li Y, Cao Y, Wu X, Liu R, Wang K (2022) HER-2-positive primary neuroendocrine neoplasms of the breast with signet ring feature: a case report and review of literature. Front Oncol 12:34–43
93.
go back to reference Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20CrossRefPubMedPubMedCentral Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20CrossRefPubMedPubMedCentral
101.
go back to reference Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817–1828. https://doi.org/10.1016/S0140-6736(20)32531-9CrossRefPubMed Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817–1828. https://​doi.​org/​10.​1016/​S0140-6736(20)32531-9CrossRefPubMed
106.
go back to reference Lai BS, Tsang JY, Poon IK, Shao Y, Chan SK, Tam FK et al (2020) The clinical significance of neuroendocrine features in invasive breast carcinomas. Oncologist 25:e1318–e1329CrossRefPubMedPubMedCentral Lai BS, Tsang JY, Poon IK, Shao Y, Chan SK, Tam FK et al (2020) The clinical significance of neuroendocrine features in invasive breast carcinomas. Oncologist 25:e1318–e1329CrossRefPubMedPubMedCentral
107.
go back to reference Rovera F, Lavazza M, La Rosa S, Fachinetti A, Chiappa C, Marelli M et al (2013) Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature. Int J Surg 11S:79–83CrossRef Rovera F, Lavazza M, La Rosa S, Fachinetti A, Chiappa C, Marelli M et al (2013) Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature. Int J Surg 11S:79–83CrossRef
108.
go back to reference Kwon SY, Bae YK, Gu MJ, Choi JE, Kang SH, Lee SJ et al (2014) Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology 64:647–659CrossRefPubMed Kwon SY, Bae YK, Gu MJ, Choi JE, Kang SH, Lee SJ et al (2014) Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology 64:647–659CrossRefPubMed
109.
go back to reference Liu YH, Tsang JYS, Ni YB, Hlaing T, Chan SK, Chan KF et al (2016) Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation. Oncotarget 7:1464–1476CrossRefPubMed Liu YH, Tsang JYS, Ni YB, Hlaing T, Chan SK, Chan KF et al (2016) Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation. Oncotarget 7:1464–1476CrossRefPubMed
111.
go back to reference Guan Y, Sun Y, Liu Z, Zhang Y, Cao M, Wang W, Tao J, Yao Y (2023) INSM1 promotes breast carcinogenesis by regulating C-MYC. Am J Cancer Res 13(8):3500–3516PubMedPubMedCentral Guan Y, Sun Y, Liu Z, Zhang Y, Cao M, Wang W, Tao J, Yao Y (2023) INSM1 promotes breast carcinogenesis by regulating C-MYC. Am J Cancer Res 13(8):3500–3516PubMedPubMedCentral
Metadata
Title
Neuroendocrine neoplasms of the breast: a review of literature
Authors
Federica Vegni
Ilenia Sara De Stefano
Federica Policardo
Pietro Tralongo
Angela Feraco
Angela Carlino
Giulia Ferraro
Qianqian Zhang
Giulia Scaglione
Nicoletta D’Alessandris
Elena Navarra
Gianfranco Zannoni
Angela Santoro
Antonino Mule
Esther Diana Rossi
Publication date
09-07-2024
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-024-03856-y